Nestlé agreed to divest its mainstream Vitamins, Minerals and Supplements business alongside its Holistic Health portfolio to a private equity firm for $1 billion. The transaction covers brands including Nature's Bounty, Pure Encapsulations, and Garden of Life—assets that generated approximately $1.4 billion in annual revenue but carried EBITDA margins in the low teens, well below the group's 17.4% consolidated operating margin.

The sale completes a multi-year exit from commoditized health categories. Nestlé retained its medical nutrition and infant formula divisions, both of which command 25%+ operating margins and serve hospital and pediatric channels with regulatory moats. The divested VMS portfolio competed in retail channels against Amazon private label, Costco Kirkland, and direct-to-consumer brands that have compressed pricing power since 2019. The buyer, unnamed in the announcement, likely sees consolidation upside in a fragmented $50 billion North American supplement market where the top ten brands hold less than 30% share.

The divestiture follows Nestlé's $2.15 billion sale of its US water brands to One Rock Capital Partners in 2021 and its $7.15 billion exit from Nestlé Waters North America regional brands the same year. CEO Mark Schneider has now shed over $10 billion in low-growth, capital-intensive assets since 2017. The capital flows toward coffee—Nespresso and Nescafé saw 8.1% organic growth in 2023—and Purina PetCare, which posted 12.3% growth in the same period. Both categories have pricing power, recurring revenue models, and defendable brand equity.

Allocators should watch Nestlé's CHF 20 billion share buyback program, authorized through 2027, for acceleration. The company has repurchased CHF 6.8 billion year-to-date and holds CHF 8.2 billion in net debt, a ratio of 0.4x EBITDA. A $1 billion cash infusion from this VMS exit, expected to close in Q2 2025, could fund an additional CHF 900 million in buybacks or bolt-on acquisitions in premium pet treats, where Nestlé trails Mars Petcare by $8 billion in revenue. The company reports full-year earnings on February 13, 2025, and guidance on capital allocation will clarify whether Schneider views the current 18.2x forward P/E as a buying opportunity or a distribution moment.

The $1 billion sale price implies a 5.5x revenue multiple, in line with private equity's recent valuations for consumer health assets with single-digit growth. The buyer inherits brands with shelf space but no pricing power, a portfolio suited for cost synergies and e-commerce expansion rather than premium repositioning.